CRON Stock Overview
Operates as a cannabinoid company that engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Cronos Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.39 |
| 52 Week High | CA$4.28 |
| 52 Week Low | CA$2.27 |
| Beta | 1.42 |
| 1 Month Change | -11.48% |
| 3 Month Change | -14.95% |
| 1 Year Change | -28.87% |
| 3 Year Change | -43.10% |
| 5 Year Change | -71.68% |
| Change since IPO | 187.95% |
Recent News & Updates
Recent updates
We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow
May 31
Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce
Apr 01We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Mar 02Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)
Feb 02Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth
Nov 09We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely
Jul 17Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors
Jun 20We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
Feb 09A Look At The Intrinsic Value Of Cronos Group Inc. (TSE:CRON)
Oct 12We're Not Very Worried About Cronos Group's (TSE:CRON) Cash Burn Rate
Sep 10Cronos Group Inc. (TSE:CRON) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 12We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth
May 19Is Cronos Group Inc. (TSE:CRON) Trading At A 47% Discount?
Jul 29An Intrinsic Calculation For Cronos Group Inc. (TSE:CRON) Suggests It's 29% Undervalued
Apr 08Shareholder Returns
| CRON | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 4.4% | 5.2% | 6.9% |
| 1Y | -28.9% | -62.4% | 8.7% |
Return vs Industry: CRON exceeded the Canadian Pharmaceuticals industry which returned -63.2% over the past year.
Return vs Market: CRON underperformed the Canadian Market which returned 7.4% over the past year.
Price Volatility
| CRON volatility | |
|---|---|
| CRON Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 12.2% |
| Market Average Movement | 9.4% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 4.0% |
Stable Share Price: CRON has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: CRON's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 459 | Mike Gorenstein | www.thecronosgroup.com |
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. The company offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brand names. Cronos Group Inc. was founded in 2012 and is based in Stayner, Canada.
Cronos Group Inc. Fundamentals Summary
| CRON fundamental statistics | |
|---|---|
| Market cap | CA$906.60m |
| Earnings (TTM) | CA$57.38m |
| Revenue (TTM) | CA$164.27m |
15.9x
P/E Ratio5.6x
P/S RatioIs CRON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRON income statement (TTM) | |
|---|---|
| Revenue | US$117.62m |
| Cost of Revenue | US$87.13m |
| Gross Profit | US$30.48m |
| Other Expenses | -US$10.60m |
| Earnings | US$41.08m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.11 |
| Gross Margin | 25.92% |
| Net Profit Margin | 34.93% |
| Debt/Equity Ratio | 0% |
How did CRON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/15 14:56 |
| End of Day Share Price | 2025/04/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cronos Group Inc. is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vahan Ajamian | Beacon Securities Limited |
| Tamy Chen | BMO Capital Markets Equity Research |
| Lisa Lewandowski | BofA Global Research |